Baidu
map

警惕苯二氮卓类与阿片类药物联合应用导致药物过量反应

2016-09-02 ·佚名 来宝网

美国健康官员周三发表了警示,将阿片类止痛剂与一类药物联合应用可能会导致致命的药物过量,这类药物包括常见的镇静剂,如安定和阿普唑仑等。 FDA特派员Robert Calif博士在媒体简报中表示,美国FDA将要求389中不同产品的包装盒上注明警告,以告知医护人员和广大患者这种潜在的致命的药物相互作用。 FDA药物评价与研究中心调整项目副主管Doug Throckmorton博士表示

美国健康官员周三发表了警示,将阿片类止痛剂与一类药物联合应用可能会导致致命的药物过量,这类药物包括常见的镇静剂,如安定和阿普唑仑等。

 

FDA特派员Robert Calif博士在媒体简报中表示,美国FDA将要求389中不同产品的包装盒上注明警告,以告知医护人员和广大患者这种潜在的致命的药物相互作用。

 

FDA药物评价与研究中心调整项目副主管Doug Throckmorton博士表示,苯二氮卓类药物,包括安定和阿普唑仑,会影响中枢神经系统,被用于治疗焦虑、失眠和癫痫等症。如果苯二氮卓类药物与阿片类药物,如羟考酮(奥施康定)和氢可酮(维柯丁)等联合使用,药物就会发生相互作用,导致昏迷或死亡。

 

巴尔的摩健康专员Leana Wen博士与FDA合作发表了新的警示,他表示,有三分之一的无意阿片类药物过量导致的死亡病例中会涉及到苯二氮卓类药物。

 

FDA表示,苯二氮卓类药物、处方阿片类止痛剂,如羟考酮和氢可酮等和含有阿片类药物的止咳剂,这些药品包装上将带有警示标识,是最严格的警示形式。

 

联合使用这些药物会危险地抑制呼吸,使人极度困倦。

 

Califf表示,最近去阿巴拉契亚山区时曾听说过类似的危险,阿巴拉契亚山区这个地区深受处方药滥用的危害。有一点很显然,我每到一个地方都会听说苯二氮卓类药物与阿片类药物过量在急救机构越来越常见了。这种因为联合应用两种药品导致的药物过量和死亡并不是最近才有的。这种趋势已经出现一段时间了,但是不幸的是,我们需要数据才能采取现在的这些行动。

 

FDA进行的总结发现有一种令人担忧的趋势,患者处方中经常将这两类药物联合应用,尽管药物相互作用很危险。

 

2002到2014年间,患者处方中同时含有阿片类止痛剂和苯二氮卓类药物的概率增加了41%。这表示有超过250万患者同时服用阿片类止痛剂和苯二氮卓类药物。

 

我们知道约有有一半的苯二氮卓类和阿片类止痛剂的处方时在同一天分发给患者的,而且是同一名医护人员开具的处方。

 

据疾病控制与预防中心统计,2014年死于处方药过量的病例史上最多。2014年,有28000人死于阿片类药物,其中有一半以上涉及到处方药的不当使用。

 

Wen表示,医生们常常在处方中同时开具阿片类药物和苯二氮卓类药物,并不了解潜在的过量风险。

 

如果患者发生了车祸,并同时伴有颈部疼痛,医生可能会给患者开阿片类药物止痛剂,苯二氮卓类药物缓解肌肉痉挛。患者服用苯二氮卓类药物治疗焦虑症也可能会被开具阿片类药物的处方来止痛,或相反。

 

Wen呼吁医生们注意新的警示,患者们也有检查自己所服用的药物。我希望患者们能自己检查自己的药箱,并问问自己这个药物是做什么用的?我真的需要它吗?副作用是什么?有可能有危险的药物联合应用反应吗?如果对这些问题有疑问,要与医生讨论。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
    2016-09-06 1e0d99ddm02(暂无匿称)

    一些药物会发生相互作用,导致昏迷或死亡。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
    2016-09-06 1e0d99ddm02(暂无匿称)

    告知医护人员和广大患者这种潜在的致命的药物相互作用。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
    2016-09-04 lhlxtx
  8. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
    2016-09-03 刘煜

    学习了谢谢!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1684164, encodeId=7bc416841647a, content=<a href='/topic/show?id=7425806967a' target=_blank style='color:#2F92EE;'>#联合应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80696, encryptionId=7425806967a, topicName=联合应用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=091d28056243, createdName=s_pl2017, createdTime=Mon Jul 24 02:31:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032317, encodeId=efc0203231ed3, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sat Mar 18 17:31:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997424, encodeId=f844199e4241c, content=<a href='/topic/show?id=bd828e850c1' target=_blank style='color:#2F92EE;'>#药物联合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87850, encryptionId=bd828e850c1, topicName=药物联合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed May 17 21:31:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112516, encodeId=1481112516e2, content=一些药物会发生相互作用,导致昏迷或死亡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:57:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112515, encodeId=d493112515a6, content=告知医护人员和广大患者这种潜在的致命的药物相互作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Tue Sep 06 16:56:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253012, encodeId=240f12530120d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309026, encodeId=54f3130902689, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596825, encodeId=ffea159682550, content=<a href='/topic/show?id=bf498e04723' target=_blank style='color:#2F92EE;'>#苯二氮卓类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87047, encryptionId=bf498e04723, topicName=苯二氮卓类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2518431662, createdName=海豹, createdTime=Sun Sep 04 05:31:00 CST 2016, time=2016-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110193, encodeId=811a11019331, content=学习了谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sat Sep 03 10:36:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110061, encodeId=b0d111006140, content=学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Sep 03 06:15:00 CST 2016, time=2016-09-03, status=1, ipAttribution=)]
    2016-09-03 zibozhouping

    学习,学习,必须不断断续续,才能进步,这么好的学习机会,不能让他错过。

    0

Baidu
map
Baidu
map
Baidu
map